Jefferies Group Reiterates $156.00 Price Target for Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (NASDAQ:ALNY) received a $156.00 target price from Jefferies Group in a report issued on Friday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Jefferies Group’s price objective points to a potential upside of 34.58% from the stock’s previous close.

Several other research firms also recently weighed in on ALNY. Morgan Stanley lifted their price objective on Alnylam Pharmaceuticals from $101.00 to $130.00 and gave the company an “equal weight” rating in a report on Thursday, November 9th. Cowen restated a “buy” rating and issued a $151.00 price objective on shares of Alnylam Pharmaceuticals in a report on Thursday, November 9th. Credit Suisse Group lifted their price objective on Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the company an “outperform” rating in a report on Friday, November 3rd. Leerink Swann lifted their price objective on Alnylam Pharmaceuticals from $132.00 to $135.00 and gave the company a “market perform” rating in a report on Thursday, January 25th. Finally, Needham & Company LLC restated a “buy” rating and issued a $152.00 price objective (up from $125.00) on shares of Alnylam Pharmaceuticals in a report on Friday, November 3rd. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Alnylam Pharmaceuticals has a consensus rating of “Buy” and an average price target of $126.98.

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at $115.92 on Friday. The stock has a market cap of $11,360.00, a price-to-earnings ratio of -21.43 and a beta of 2.68. Alnylam Pharmaceuticals has a one year low of $40.93 and a one year high of $147.63. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.38) by ($0.10). The company had revenue of $37.90 million for the quarter, compared to analysts’ expectations of $19.31 million. Alnylam Pharmaceuticals had a negative net margin of 545.95% and a negative return on equity of 48.88%. The firm’s revenue for the quarter was up 116.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.32) earnings per share. sell-side analysts predict that Alnylam Pharmaceuticals will post -5.69 EPS for the current fiscal year.

In other news, VP Michael Mason sold 36,745 shares of the company’s stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the transaction, the vice president now owns 6,352 shares in the company, valued at $835,859.68. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Laurie Keating sold 6,249 shares of the company’s stock in a transaction dated Wednesday, December 20th. The shares were sold at an average price of $121.20, for a total transaction of $757,378.80. Following the transaction, the senior vice president now owns 17,749 shares in the company, valued at approximately $2,151,178.80. The disclosure for this sale can be found here. Insiders sold 220,409 shares of company stock valued at $28,667,017 over the last quarter. 4.30% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. The Manufacturers Life Insurance Company increased its holdings in shares of Alnylam Pharmaceuticals by 7.0% during the second quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 167 shares in the last quarter. Prudential Financial Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 4.8% during the second quarter. Prudential Financial Inc. now owns 4,404 shares of the biopharmaceutical company’s stock valued at $351,000 after acquiring an additional 200 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Alnylam Pharmaceuticals by 0.4% during the third quarter. Dimensional Fund Advisors LP now owns 180,058 shares of the biopharmaceutical company’s stock valued at $21,156,000 after acquiring an additional 629 shares in the last quarter. Great West Life Assurance Co. Can increased its holdings in shares of Alnylam Pharmaceuticals by 8.5% during the third quarter. Great West Life Assurance Co. Can now owns 8,904 shares of the biopharmaceutical company’s stock valued at $1,050,000 after acquiring an additional 695 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Alnylam Pharmaceuticals by 10.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 7,200 shares of the biopharmaceutical company’s stock valued at $915,000 after acquiring an additional 700 shares in the last quarter. Hedge funds and other institutional investors own 88.39% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Jefferies Group Reiterates $156.00 Price Target for Alnylam Pharmaceuticals (ALNY)” was originally published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2018/02/09/alnylam-pharmaceuticals-alny-rating-reiterated-by-jefferies-group.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply